Get the latest news on Avisa Diagnostics stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on FOGCF performance

Latest Avisa Diagnostics Stock News | OTC:FOGCF | Benzinga

Avisa Diagnostics Inc is a clinical-stage medical device company developing the Avisa BreathTest, a novel drug/device biomarker technology platform that enables the ultra-rapid detection of virulent bacterial pathogens, detecting and monitoring bacterial load after the patient inhales or ingests its proprietary drug substrates. The company has established clinical proof-of-concept through trials in cystic fibrosis, tuberculosis and community acquired pneumonia, which demonstrated positive safety and clinical efficacy results. Avisa is planning pivotal trials in Post-COVID-19 bronchiectasis and ventilator-associated pneumonia and plans to submit Investigational Device Exemption applications to the U.S. FDA for these trials.

AVISA DIAGNOSTICS INC by Avisa Diagnostics Inc.

Comments

Avisa Diagnostics Stock News

News

Latest Avisa Diagnostics Stock News | OTC:FOGCF | Benzinga

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga